Market Research Reports

Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018

72pages
Published Date: 2014-01-24
 

Description


The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market. 

Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter’s forces, competitive landscape and company profiles of key players.

The report categorizes the global ophthalmic drugs market based on major eye disorders, treatment drugs and geography. The treatment drugs market comprises treatment of major eye disorders such as glaucoma, dry eye drugs, retinal diseases and ocular inflammatory diseases. The market is further segmented on the basis of prescription based drugs, OTC drugs and pipeline drugs in different eye disorder areas. In the segment of geographic analysis, the report identifies and analyses market sizes and forecast of North America, Europe, Asia Pacific and Rest of the World (RoW). North America region covers the scenario of the US. Europe region covers the scenario of France, Germany and the UK. Asia Pacific region highlights the scenario of India, China and Japan. 

Table of Contents



Chapter 1 Preface 8
1.1 Report Description 8
1.2 Research Methodology 8

Chapter 2 Executive Summary 10

Chapter 3 Ophthalmic Drugs – Industry Analysis 11
3.1 Introduction 11
3.2 Market Drivers and Opportunities 11
      3.2.1 Increasing prevalence of eye disorders 12
      3.2.2 Global aging population 12
      3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries 13
      3.2.4 Technological changes in drug delivery techniques 14
      3.2.5 Increasing prevalence of lifestyle associated diseases 14
3.3 Restraints and Challenges 15
      3.3.1 Lack of awareness among people regarding eye disorders 15
      3.3.2 Drying pipeline of ophthalmic drugs 15
      3.3.3 Patent expiration of blockbuster ophthalmic drugs 16
      3.3.4 Absence of health insurance in developing countries 16

Chapter 4 Ophthalmic Drugs Market Trends 18
4.1 Increased focus on combination therapy 18
4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market 18

Chapter 5 Porter’s Five Force Analysis 20
5.1 Bargaining power of buyers 20
5.2 Bargaining power of suppliers 21
5.3 Threat of new entrants 21
5.4 Threat from substitutes 21
5.5 Degree of competition 21

Chapter 6 Global Market Size and Forecast 22

Chapter 7 Ophthalmic Drugs Market – Treatment Drugs 25
7.1 Dry eye drugs 25
      7.1.1 Existing 25
      7.1.2 Pipeline 26
7.2 Retinal drugs 27
      7.2.1 Existing 27
      7.2.2 Pipeline 28
7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs 29
      7.3.1 Existing 29
      7.3.2 Pipeline 30
7.4 Anti-glaucoma drugs 31
      7.4.1 Existing 31
      7.4.2 Pipeline 32

Chapter 8 Ophthalmic Drugs Market: Regional Analysis 34
8.1 Scenario in North America 34
      8.1.1 Scenario in the US 36
8.2 Scenario in Europe 38
      8.2.1 Scenario in France 41
      8.2.2 Scenario in Germany 42
      8.2.3 Scenario in the UK 44
8.3 Scenario in Asia Pacific 46
      8.3.1 Scenario in India 49
      8.3.2 Scenario in China 50
      8.3.3 Scenario in Japan 52

Chapter 9 Prescription vs. Over the Counter Drugs 55

Chapter 10 Competitive Landscape 57

Chapter 11 Company Profiles 62
11.1 Santen Pharmaceutical 62
      11.1.1 Overview 62
      11.1.2 Products and segments 62
      11.1.3 Financial Performance 62
11.2 Pfizer 63
      11.2.1 Overview 63
      11.2.2 Products & Segments 63
      11.2.3 Financial Performance 63
11.3 Novartis 64
      11.3.1 Overview 64
      11.3.2 Products & Segments 64
      11.3.3 Financial Performance 65
11.4 Merck 66
      11.4.1 Overview 66
      11.4.2 Products & Segments 66
      11.4.3 Financial Performance 66
11.5 Roche 68
      11.5.1 Overview 68
      11.5.2 Products & Segments 68
      11.5.3 Financial Performance 68
11.6 Allergan 70
      11.6.1 Overview 70
      11.6.2 Products & Segments 70
      11.6.3 Financial Performance 70

List of Figures 

FIG. 1 Profiles of aging population in major countries (%, 2000-2050) 13
FIG. 2 Global ophthalmic drugs market: Porter’s five force analysis 20
FIG. 3 Key players market share in the global ophthalmic drugs market in 2012 57
FIG. 4 Ophthalmic drugs market strategic developments (2011-2013) 58

List of Tables

TABLE 1 Drivers for ophthalmic drugs market: Impact analysis 11
TABLE 2 Global data on visual impairment, by region (million, 2002 and 2010) 12
TABLE 3 Restraints for ophthalmic drugs market: Impact analysis 15
TABLE 4 Out of pocket expenditure of developing and developed countries 17
TABLE 5 Major combination therapy drugs worldwide 18
TABLE 6 Major merger and acquisitions in the ophthalmic drug market 19
TABLE 7 Global Ophthalmic drugs market size, by geography 2008-2012 (USD million) 22
TABLE 8 Global Ophthalmic drugs market size, by geography 2013-2018(USD millions) 23
TABLE 9 Global Ophthalmic drugs market size, by disease 2008-2012 (USD million) 23
TABLE 10 Global Ophthalmic drugs market size, by disease 2013-2018 (USD million) 24
TABLE 11 Dry eye drugs market 2010-2012 (USD million) 25
TABLE 12 Dry eye drugs market 2013-2018 (USD million) 26
TABLE 13 Major dry eye drugs pipeline 26
TABLE 14 Retinal drugs market 2010-2012 (USD million) 27
TABLE 15 Retinal drugs market 2013-2018 (USD million) 28
TABLE 16 Major retinal disease drugs pipeline 28
TABLE 17 Anti-allergy/inflammatory drugs market 2010-2012 (USD million) 29
TABLE 18 Anti-allergy/inflammatory drugs market 2013-2018 (USD million) 30
TABLE 19 Major anti-inflammatory/allergy/anti-infective drugs pipeline 30
TABLE 20 Prevalence of glaucoma, by geographic regions (million, 2010-2020) 31
TABLE 21 Major anti-glaucoma drugs market 2010-2012 (USD million) 32
TABLE 22 Major anti-glaucoma drugs market 2013-2018 (USD million) 32
TABLE 23 Anti-glaucoma drugs pipeline 33
TABLE 24 North America Ophthalmic drugs market size, by geography 2008-2012 (USD million) 34
TABLE 25 North America Ophthalmic drugs market size, by geography 2013-2018 (USD million) 35
TABLE 26 North America Ophthalmic drugs market size, by disease 2008-2012 (USD million) 35
TABLE 27 North America ophthalmic drugs market, by disease 2013-2018 (USD million) 36
TABLE 28 Ophthalmic drugs market, by disease in US 2008-2012(USD million) 37
TABLE 29 Ophthalmic drugs market by disease in US 2013-2018 (USD million) 37
TABLE 30 European Ophthalmic drugs market size, by geography 2008-2012 (USD million) 38
TABLE 31 European Ophthalmic drugs market size, by geography 2013-2018 (USD million) 39
TABLE 32 European ophthalmic drugs market by disease 2008-2012 (USD million) 40
TABLE 33 European ophthalmic drugs market by disease 2013-2018 (USD million) 40
TABLE 34 French ophthalmic drugs market by disease 2008-2012 (USD million) 41
TABLE 35 French ophthalmic drugs market, by disease 2013-2018 (USD million) 42
TABLE 36 German Ophthalmic drugs market, by disease 2008-2012 (USD million) 43
TABLE 37 German ophthalmic drugs market, by disease 2013-2018 (USD million) 43
TABLE 38 The UK ophthalmic drugs market, by disease 2008-2012 (USD million) 45
TABLE 39 The UK ophthalmic drugs market, by disease 2013-2018 (USD million) 45
TABLE 40 Asian Ophthalmic drugs market size, by country 2008-2012 (USD million) 46
TABLE 41 Asian Ophthalmic drugs market size, by geography 2013-2018 (USD million) 47
TABLE 42 Asian ophthalmic drugs market, by disease 2008-2012 (USD million) 47
TABLE 43 Asian ophthalmic drugs market, by disease 2013-2018 (USD million) 48
TABLE 44 Indian ophthalmic drugs market, by disease 2008-2012 (USD million) 49
TABLE 45 Indian ophthalmic drugs market, by disease 2013-2018 (USD million) 50
TABLE 46 Chinese ophthalmic drugs market, by disease 2008-2012 (USD million) 51
TABLE 47 Chinese ophthalmic drugs market, by disease 2013-2018 (USD million) 52
TABLE 48 Japanese ophthalmic drugs market, by disease 2008-2012 (USD million) 53
TABLE 49 Japanese ophthalmic drugs market, by disease 2013-2018 (USD million) 53
TABLE 50 Ophthalmic drugs market, by prescription vs. over the counter drugs 2008-2012 (USD million) 55
TABLE 51 Ophthalmic drugs market, by prescription vs. over the counter drugs 2013-2018 (USD million) 56
TABLE 52 Major product launches in ophthalmic drugs market (2011-2013) 59
TABLE 53 R&D initiatives in ophthalmic drugs market (2012-2013) 60
TABLE 54 Mergers and acquisitions in ophthalmic drugs market (2011-2013) 61

Enquiry Before Buying


Free Market Analysis


Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.

Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries. 

North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market
Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 – 2018.Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.

Novartis (Alcon) is the leading player in the global ophthalmic drugs market with a share of about 24% in 2012. Other major players of ophthalmic drugs market include Allergan, Santen, Pfizer, Merck and Roche and others.
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research